BioStem Q2 Revenue Jumps 29% Sequentially; Raises Full-Year Guidance
BSEM sits 26% above its 52-week low of $3.01 on elevated volume (2.7× avg).
Summary
BioStem Technologies reported strong Q2 revenue growth of 29% sequentially and raised its full-year guidance, but continues to burn cash with a $9.0 million net loss.
Key Events · Earnings and Guidance · BSEM
-
Q2 Revenue Up 29% Sequentially
Net revenue reached $7.9 million in Q2 2026, up from $6.1 million in Q1 2026, driven by Neox and Clarix product sales.
-
Full-Year Guidance Raised
Company now expects full-year 2026 revenue of $26-$29 million, up from prior guidance of $25-$29 million.
-
GAAP Net Loss of $9.0M
Q2 2026 net loss was $9.0 million, or $0.52 per share, compared to a $10,613 net income in Q2 2025.
-
Cash Burn Continues
Cash used in operations was $5.5 million in Q2, reducing cash to $7.0 million as of June 30, 2026, from $13.7 million at end of Q1.
Analysis · BSEM · Life Sciences
BioStem reported Q2 revenue of $7.9 million, up 29% from Q1, and raised its full-year 2026 revenue guidance to $26-$29 million. The company also disclosed a $9.0 million GAAP net loss and cash burn of $5.5 million, leaving $7.0 million in cash. The revenue growth and guidance raise are positive, but the ongoing losses and cash consumption remain a concern, especially with a $10 million payment obligation due by September 15, 2026.
At the time of this filing, BSEM was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.8M. The 52-week trading range was $3.01 to $10.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.